Clinical Trials Logo

Clinical Trial Summary

In current practice, options for venous and lymphatic malformations remain limited. Recently an oral medication, sirolimus, has been found to benefit patients when taken once or twice a day for several months. Unfortunately there are many side effects associated with this medication, some of which can be severe including, neutropenia, oral ulcerations, and lab abnormalities. The purpose of this study is to determine if once weekly dosed sirolimus will be effective for the treatment of venous and lymphatic malformations. Additionally, the study will evaluate patient satisfaction and identify adverse effects. Participants will be on the medication for 6 months with an option to continue after this time period.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT04861064
Study type Interventional
Source Medical University of South Carolina
Contact Alexandra Ritter, BS
Phone 843-876-3209
Email [email protected]
Status Not yet recruiting
Phase Phase 2
Start date May 2021
Completion date May 2022

See also
  Status Clinical Trial Phase
Recruiting NCT04409145 - First in Human Trial of Topical VT30 in Pts With Venous/Lymphatic Malformations Assoc With PIK3CA or TEK Gene Mutations Phase 1/Phase 2
Completed NCT04637997 - Influence of Flat-knitted Compression Stockings Class I and II on Venous Malformations N/A
Not yet recruiting NCT04258046 - Trametinib in the Treatment of Complicated Extracranial Arterial Venous Malformation Phase 2
Recruiting NCT03767660 - Efficacy of Rapamycin (Sirolimus) in the Treatment of BRBNS, Hereditary or Sporadic Venous Malformation Phase 4
Recruiting NCT04486599 - Electromagnetic Navigation During Ultrasound Guided Foam Sclerotherapy for Venous Malformations N/A
Recruiting NCT01347294 - Compare Two Different Sclerosing Agents in the Treatment of Venous Malformations Phase 4
Recruiting NCT04836884 - Vascular Anomaly Pathology and Genomics Biopsy Study N/A